181 related articles for article (PubMed ID: 36603035)
21. Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection.
Fralish BH; Tarleton RL
Vaccine; 2003 Jun; 21(21-22):3070-80. PubMed ID: 12798651
[TBL] [Abstract][Full Text] [Related]
22. A novel multi-epitope recombinant protein elicits an antigen-specific CD8+ T cells response in Trypanosoma cruzi-infected mice.
González-López C; Chen WH; Alfaro-Chacón A; Villanueva-Lizama LE; Rosado-Vallado M; Ramirez-Sierra MJ; Teh-Poot CF; Pollet J; Asojo O; Jones KM; Hotez PJ; Elena Bottazzi M; Cruz-Chan JV
Vaccine; 2022 Oct; 40(45):6445-6449. PubMed ID: 36184402
[TBL] [Abstract][Full Text] [Related]
23. Protective immunity against trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase.
Vasconcelos JR; Hiyane MI; Marinho CR; Claser C; Machado AM; Gazzinelli RT; Bruña-Romero O; Alvarez JM; Boscardin SB; Rodrigues MM
Hum Gene Ther; 2004 Sep; 15(9):878-86. PubMed ID: 15353042
[TBL] [Abstract][Full Text] [Related]
24. Critical contribution of immunoproteasomes in the induction of protective immunity against Trypanosoma cruzi in mice vaccinated with a plasmid encoding a CTL epitope fused to green fluorescence protein.
Chou B; Hisaeda H; Shen J; Duan X; Imai T; Tu L; Murata S; Tanaka K; Himeno K
Microbes Infect; 2008 Mar; 10(3):241-50. PubMed ID: 18321749
[TBL] [Abstract][Full Text] [Related]
25. Identification of Trypanosoma cruzi trans-sialidase family members as targets of protective CD8+ TC1 responses.
Wizel B; Nunes M; Tarleton RL
J Immunol; 1997 Dec; 159(12):6120-30. PubMed ID: 9550413
[TBL] [Abstract][Full Text] [Related]
26. Deficiency of antigen-specific B cells results in decreased Trypanosoma cruzi systemic but not mucosal immunity due to CD8 T cell exhaustion.
Sullivan NL; Eickhoff CS; Sagartz J; Hoft DF
J Immunol; 2015 Feb; 194(4):1806-18. PubMed ID: 25595788
[TBL] [Abstract][Full Text] [Related]
27. Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi.
Gupta S; Garg NJ
Vaccine; 2012 Nov; 30(50):7179-86. PubMed ID: 23079191
[TBL] [Abstract][Full Text] [Related]
28. Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy.
Katae M; Miyahira Y; Takeda K; Matsuda H; Yagita H; Okumura K; Takeuchi T; Kamiyama T; Ohwada A; Fukuchi Y; Aoki T
Infect Immun; 2002 Sep; 70(9):4833-40. PubMed ID: 12183527
[TBL] [Abstract][Full Text] [Related]
29. Experimental Nanovaccine Offers Protection Against Repeat Exposures to
Chowdhury IH; Lokugamage N; Garg NJ
Front Immunol; 2020; 11():595039. PubMed ID: 33414785
[TBL] [Abstract][Full Text] [Related]
30. Insufficient TLR activation contributes to the slow development of CD8+ T cell responses in Trypanosoma cruzi infection.
Padilla AM; Simpson LJ; Tarleton RL
J Immunol; 2009 Jul; 183(2):1245-52. PubMed ID: 19553540
[TBL] [Abstract][Full Text] [Related]
31. Paraflagellar rod protein-specific CD8+ cytotoxic T lymphocytes target Trypanosoma cruzi-infected host cells.
Wrightsman RA; Luhrs KA; Fouts D; Manning JE
Parasite Immunol; 2002 Aug; 24(8):401-12. PubMed ID: 12406194
[TBL] [Abstract][Full Text] [Related]
32. CD8+ T cells in Trypanosoma cruzi infection.
Tarleton RL
Semin Immunopathol; 2015 May; 37(3):233-8. PubMed ID: 25921214
[TBL] [Abstract][Full Text] [Related]
33. Biological and immunological characterization of recombinant Yellow Fever 17D viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+ T cell epitope at two distinct regions of the genome.
Nogueira RT; Nogueira AR; Pereira MC; Rodrigues MM; Galler R; Bonaldo MC
Virol J; 2011 Mar; 8():127. PubMed ID: 21418577
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease.
Bontempi IA; Vicco MH; Cabrera G; Villar SR; González FB; Roggero EA; Ameloot P; Callewaert N; Pérez AR; Marcipar IS
Vaccine; 2015 Mar; 33(10):1274-83. PubMed ID: 25625671
[TBL] [Abstract][Full Text] [Related]
35. Nasal immunization with a L. lactis-derived trans-sialidase antigen plus c-di-AMP protects against acute oral T. cruzi infection.
Pacini MF; González FB; Dinatale B; Bulfoni Balbi C; Villar SR; Farré C; Lupi G; Espariz M; Blancato VS; Magni C; Marcipar I; Pérez AR
Vaccine; 2022 Apr; 40(15):2311-2323. PubMed ID: 35279330
[TBL] [Abstract][Full Text] [Related]
36. Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection.
Barbosa RP; Filho BG; Dos Santos LI; Junior PA; Marques PE; Pereira RV; Cara DC; Bruña-Romero O; Rodrigues MM; Gazzinelli RT; Machado AV
PLoS One; 2013; 8(4):e61795. PubMed ID: 23637908
[TBL] [Abstract][Full Text] [Related]
37. The SA85-1.1 protein of the Trypanosoma cruzi trans-sialidase superfamily is a dominant T-cell antigen.
Millar AE; Kahn SJ
Infect Immun; 2000 Jun; 68(6):3574-80. PubMed ID: 10816514
[TBL] [Abstract][Full Text] [Related]
38. Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.
Gupta S; Garg NJ
PLoS Negl Trop Dis; 2010 Aug; 4(8):e797. PubMed ID: 20706586
[TBL] [Abstract][Full Text] [Related]
39.
Puerta CJ; Cuellar A; Lasso P; Mateus J; Gonzalez JM
Front Cell Infect Microbiol; 2022; 12():1075717. PubMed ID: 36683674
[No Abstract] [Full Text] [Related]
40. Limited Foxp3
Araujo Furlan CL; Tosello Boari J; Rodriguez C; Canale FP; Fiocca Vernengo F; Boccardo S; Beccaria CG; Adoue V; Joffre O; Gruppi A; Montes CL; Acosta Rodriguez EV
Front Immunol; 2018; 9():2555. PubMed ID: 30455700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
